Goldfinch Bio to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the 38th Annual J.P. Morgan Healthcare Conference. During the presentation, Dr. Johnson will provide a…
Details